1Druker BJ,Talpaz M,Resta DJ,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [ J ]. N Engl J Med ,2001,344 : 1031 - 1037.
2Deininger MW. Management of early stage disease [ J ]. Hematol Am Soc Hematol Educ Program, 2005,174 - 182 [ Pubmed - in process].
3Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympboblastic leukemia with the Philadelphia chromosome [ J ]. N Engl J Med, 2001,344 : 1038 - 1042.
4Silver RT,Talpaz M,Sawyers CL,et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase ( AP ), or blast crisis ( BC ) chronic myeloid leukemia (CML) treated with imatinib in three large phase Ⅱ trials [ J ]. Blood, 2004, 104(Suppl) :11a
5Kantarjian H, Sawyers C, Hochhaus A, et al. International ST1571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia [ J ]. N Engl J Med,2002,346:645 - 652.
6O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia [ J ]. N Engl J Med, 2003,348 : 994 -1004.
7Druker B, Guilhot F, O'Brien S, et al. Long-term benefits of imatinib(IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase(CML-CP) :the 5-year update from the IRIS study [ J ]. Proc ASC0,2006,24:6506.
8Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STL571 (IRIS) Study Group, Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [ J ]. N Engl J Med,2003,349:1423 - 1432.
9Garcia-Manero G,Faderl S, O'Brien S, et al. Chronic myelogenous leukemia:a review and update of therapeutic strategies[ J ]. Cancer,2003,98:437 - 457.
10Atallah E, Durand JB, Kantaljian HM, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy [ J ]. Blood,2007,20[ Epub ahead of print].
